4.5 Article

ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

期刊

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/ijgc-2020-002073

关键词

ovarian cancer; medical oncology; fallopian tube neoplasms; peritoneal neoplasms

资金

  1. UK from Cancer Research UK [A19714 CRUK/15/074]
  2. Priority-driven Collaborative Cancer Research Scheme
  3. Cancer Australia [1100619]
  4. UCL
  5. Cancer Research UK
  6. UCL Cancer Trials Centre

向作者/读者索取更多资源

The ICON9 trial aims to investigate the efficacy of maintenance treatment with cediranib and olaparib in recurrent ovarian cancer, with an estimated completion of recruitment in 2024 and presentation of results in 2025.
Background Two novel biological agents-cediranib targeting angiogenesis, and olaparib targeting DNA repair processes-have individually led to an improvement in ovarian cancer control. The aim of ICON9 is to investigate the combination of cediranib and olaparib maintenance in recurrent ovarian cancer following platinum-based therapy. Primary objective To assess the efficacy of maintenance treatment with olaparib in combination with cediranib compared with olaparib alone following a response to platinum-based chemotherapy in women with platinum-sensitive ovarian, fallopian tube or peritoneal cancer during first relapse. Study hypothesis Maintenance therapy with cediranib and olaparib in combination is associated with improved patient outcomes compared with olaparib alone. Trial design International phase III randomized controlled trial. Following a response to platinum-based chemotherapy patients are randomized 1:1 to either oral olaparib and cediranib (intervention arm) or oral olaparib alone (control arm). Major inclusion criteria Patients with a known diagnosis of high grade serous or endometrioid carcinoma of the ovary, fallopian tube or peritoneum, progressing more than 6 months after first-line platinum-based chemotherapy, who have responded to second-line platinum-based chemotherapy. Primary endpoints Progression-free and overall survival. Co-primary endpoints to be assessed using a fixed-sequence gatekeeping approach: (1) progression-free survival, all patients; (2) progression-free survival, BRCA wild type; (3) overall survival, all patients; (4) overall survival, BRCA wild type. Sample size 618 patients will be recruited. Estimated dates for completing accrual and presenting results Accrual is expected to be completed in 2024 with presentation of results in 2025.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据